← Back to Search

Monoclonal Antibodies

Monoclonal Antibody for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 and over
Cardiovascular criteria met: Left ventricular function normal, No significant cardiovascular disease, No myocardial infarction within the past 6 months, No New York Heart Association class III or IV heart disease, No active ischemia by EKG
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying a monoclonal antibody to see how well it works in treating patients with acute myelogenous leukemia that did not respond to standard treatment.

Who is the study for?
This trial is for adults with acute myelogenous leukemia (AML) that didn't improve after standard treatment. Participants must be over 18, have a good performance status, no severe infections or heart disease, and normal liver and kidney function. Pregnant women can't join, and participants must use contraception.Check my eligibility
What is being tested?
The study tests the effectiveness of a monoclonal antibody in patients whose AML did not respond to previous treatments. It's a Phase II trial aiming to see if this therapy can target and kill cancer cells without harming healthy ones.See study design
What are the potential side effects?
Monoclonal antibodies may cause allergic reactions, fatigue, fever, chills or nausea. They might also affect blood cell counts leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My heart is healthy with no recent heart attacks or severe heart disease.
Select...
I can perform most of my daily activities without assistance.
Select...
My AML did not respond to standard chemotherapy as part of a specific study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
358 Previous Clinical Trials
26,076 Total Patients Enrolled
21 Trials studying Leukemia
221 Patients Enrolled for Leukemia
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,646 Total Patients Enrolled
1,508 Trials studying Leukemia
379,376 Patients Enrolled for Leukemia
Christos E. Emmanouilides, MDStudy ChairJonsson Comprehensive Cancer Center
11 Previous Clinical Trials
50 Total Patients Enrolled
2 Trials studying Leukemia

Media Library

Leukemia Research Study Groups:
Leukemia Clinical Trial 2023: Monoclonal Antibody Highlights & Side Effects. Trial Name: NCT00006084 — Phase 2
Monoclonal Antibody (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006084 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people still able to join this research project?

"Unfortunately, this specific trial is not taking patients at the moment. However, there are over 1500 other trials that might be a fit for you."

Answered by AI

What are the risks associated with this treatment?

"While there is some data supporting the safety of this Phase 2 treatment, there is currently no information indicating that it is effective."

Answered by AI
~15 spots leftby Mar 2025